System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Fontanet Bijou is an expert in Hematology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Fontanet Bijou in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Fontanet Bijou has authored 109 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 11 of them ongoing. SLR score: 692 (community average: 125). How the SLR is computed.

LeadR Profile

Fontanet Bijou Institut Bergonié France
692 ScienceLeadR Reputation 692

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 109

Citations

Citations: 1 613 1st author: 5 Last author: 0 Unique author: 0

Main journals

Blood 30
Hematol Oncol 11
J Clin Oncol 9
Hemasphere 8
Br J Haematol 5

Best Journals

J Clin Oncol 9

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
PMID 42669939 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes		Br J Haematol20260
Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).
PMID 42644287 — activities of daily living, brentuximab vedotin, hodgkin disease, lymphoma, aged, therapeutics		Br J Haematol20260
BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.
PMID 41958072 — cells, hematology, rituximab, vemurafenib		Br J Haematol20260
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.
PMID 41922143 — lymphoma, follicular, growth, lymphoma, neoplasms, therapeutics		ESMO Open20260
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
PMID 41915772 — lymphoma, follicular, hematology, lymphoma, rituximab, lenalidomide, therapeutics		Blood20260

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 11
Phase 2 6
N/A 5
Phase 1 3
Phase 1/Phase 2 2

By status:

Completed 10
Recruiting 9
Active not recruiting 6
Not yet recruiting 1
Terminated 1

By type:

Interventional 22
Observational 5

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 1
multicentricup10 24

Main Topics

Ongoing Clinical Trials

11 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459 — cells, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, aged, protein-tyrosine kinases, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics, b-lymphocytes		Phase 2Not yet recruiting2026
An unblinded multi center study evaluating long term treatment with Zanubrutinib (BGB 3111) regimens in patients with blood cancer in the lymph node
2024-511267-28-00 — cells, blood, lymph nodes, neoplasms, multiple chronic conditions, lymph, therapeutics, b-lymphocytes		Phase 3Active not recruiting2021
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma
2023-506899-27-00 — cells, safety, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, oxaliplatin, rituximab, b-lymphocytes		Phase 3Active not recruiting2021
A Phase 1 dose determining study of EXS73565 in participants with relapsed or refractory B cell malignancies
2024-516869-36-00 — cells, b-lymphocytes		Phase 1Recruiting2025
MARSUN Evaluation of the benefits of the combination of Mosunetuzumab Lenalidomide versus a treatment chosen by the investigator in Patients with Relapsed or Refractory Marginal Zone Lymphoma
2022-501810-77-00 — lymphoma, lenalidomide, therapeutics		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS